8-K Announcements
6Material company update
May 7, 2026·SEC
Material company update
Feb 26, 2026·SEC
Material company update
Feb 23, 2026·SEC
Organogenesis Holdings Inc.(ORGO)Earnings, Financials & Key Ratios
ORGO•NASDAQ
16.3× P/E·Price updated Jun 19, 2026
AboutOrganogenesis Holdings Inc., a regenerative medicine company develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane wound covering in which viable cells growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, and cytokines; NuShield, a wound covering tissue includes both amnion and chorion membranes for spongy/intermediate layer intact; PuraPly , a antimicrobial barrier that enables conformability and fluid drainage; and Novachor, an amniotic membrane wound covering in which viable cells, growth factors/cytokines, and ECM proteins are preserved. Its surgical and sports medicine products comprise NuCel, a dehydrated placental tissue surgically applied to the target tissue to support native healing; ReNu, a cryopreserved suspension used to support healing of soft tissues; and FiberOS and OCMP used as a bone void filler primarily in orthopedic and neurosurgical applications. The company's pipeline products include PuraPly XT and PuraPly MZ to treat chronic, acute, and open wounds; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales force and independent agencies. The company was founded in 1985 and is headquartered in Canton, Massachusetts.Show more
- Revenue$563M+16.8%
- EBITDA$83M+426.0%
- Net Income$37M+4201.0%
- EPS (Diluted)0.15+1600.0%
- Gross Margin75.57%-0.5%
- EBITDA Margin14.71%+350.3%
- Operating Margin9.92%+3827.6%
- Net Margin6.58%+3582.7%
- ROE9.04%+3386.5%
ORGO Key Insights
Organogenesis Holdings Inc. (ORGO) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y profit CAGR of 16.5%
- ✓Strong 5Y sales CAGR of 10.7%
- ✓Trading at only 0.7x book value
✗Weaknesses
- ✗Weak 3Y average ROE of 3.7%
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 17 (bottom 17%)
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when ORGO posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ORGO Price & Volume
Organogenesis Holdings Inc. (ORGO) stock price & volume — 10-year historical chart
Loading chart...
ORGO Growth Metrics
Organogenesis Holdings Inc. (ORGO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years10.73%
3 Years7.68%
TTM11.95%
Profit CAGR
10 Years-
5 Years16.53%
3 Years33.59%
TTM98.21%
EPS CAGR
10 Years-
5 Years0%
3 Years7.72%
TTM4.81%
Return on Capital
10 Years1%
5 Years9.2%
3 Years5.05%
Last Year12.16%
ORGO Recent Earnings
Organogenesis Holdings Inc. (ORGO) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 7/12 qtrs (58%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.37-27.6%
$0.29
Rev
$36M-16.2%
$43M
Q1 2026
Feb 26, 2026Metric
Actual
Est
EPS
$0.31+44.2%
$0.21
Rev
$225M+30.4%
$173M
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.18-14.3%
$0.21
Rev
$151M-12.6%
$173M
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.09-228.6%
$0.07
Rev
$101M-24.7%
$134M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.37vs $0.29-27.6% | $36Mvs $43M-16.2% |
| Q1 2026 | Feb 26, 2026 | $0.31vs $0.21+44.2% | $225Mvs $173M+30.4% |
| Q4 2025 | Nov 6, 2025 | $0.18vs $0.21-14.3% | $151Mvs $173M-12.6% |
| Q3 2025 | Aug 7, 2025 | $0.09vs $0.07-228.6% | $101Mvs $134M-24.7% |
Based on last 12 quarters of dataView full earnings history →
ORGO Peer Comparison
Organogenesis Holdings Inc. (ORGO) competitors in Therapy-focused branded biopharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 MDXG | 545.24M | 3.67 | 11.47 | 19.99% | 7.88% | 12.86% | 0.09 | |
 NVCR | 1.62B | 14.28 | -11.70 | 8.28% | -25.66% | -50.82% | 0.85 | |
 TELA | 36.85M | 0.82 | -0.99 | 15.84% | -49.3% | -13.44% | 8.82 | |
 APOG | 887.72M | 41.27 | 16.38 | 3.21% | 3.85% | 10.79% | 0.56 | |
 IONS | 12.25B | 74.12 | -31.14 | 33.87% | -30.87% | -58.57% | 5.35 | |
 MGRX | 3.33M | 0.33 | -0.16 | -25.96% | -46.33% | -120.72% | 0.02 | |
 SKIN | 85.9M | 0.66 | -4.14 | -10.02% | -2.03% | -9.41% | 6.20 | |
 XTNT | 61.8M | 0.44 | 14.69 | 14.21% | 1.5% | 3.68% | 0.56 |
Compare ORGO vs Peers
Organogenesis Holdings Inc. (ORGO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ORGO Income Statement
Organogenesis Holdings Inc. (ORGO) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 193.45M | 260.98M | 338.3M | 467.36M | 450.89M | 433.14M | 482.04M | 563.03M | 513.57M |
Revenue Growth % | - | - | 34.91% | 29.63% | 38.15% | -3.52% | -3.94% | 11.29% | 16.8% | 11.95% |
Cost of Goods Sold | 4.59M | 68.81M | 75.95M | 87.32M | 114.2M | 105.02M | 106.48M | 115.74M | 137.52M | 151.94M |
COGS % of Revenue | - | 35.57% | 29.1% | 25.81% | 24.44% | 23.29% | 24.58% | 24.01% | 24.43% | - |
Gross Profit | -4.59M▲ 0% | 124.64M▲ 2814.4% | 185.03M▲ 48.5% | 250.98M▲ 35.6% | 353.16M▲ 40.7% | 345.87M▼ 2.1% | 326.66M▼ 5.6% | 366.3M▲ 12.1% | 425.51M▲ 16.2% | 361.62M▲ 0% |
Gross Margin % | - | 64.43% | 70.9% | 74.19% | 75.56% | 76.71% | 75.42% | 75.99% | 75.57% | 70.41% |
Gross Profit Growth % | -2100.23% | 2814.41% | 48.45% | 35.64% | 40.71% | -2.06% | -5.56% | 12.14% | 16.16% | - |
Operating Expenses | 4.59M | 172.7M | 214.89M | 224.28M | 280.94M | 323.57M | 314.13M | 367.58M | 369.64M | 350.61M |
OpEx % of Revenue | - | 89.28% | 82.34% | 66.3% | 60.11% | 71.76% | 72.52% | 76.26% | 65.65% | - |
Selling, General & Admin | 4.59M | 161.96M | 200.09M | 204.19M | 250.2M | 283.81M | 269.75M | 294.51M | 326.24M | 318.91M |
SG&A % of Revenue | - | 83.72% | 76.67% | 60.36% | 53.53% | 62.94% | 62.28% | 61.1% | 57.94% | - |
Research & Development | 0 | 10.74M | 14.8M | 20.09M | 30.74M | 39.76M | 44.38M | 50.27M | 44.54M | 49.06M |
R&D % of Revenue | - | 5.55% | 5.67% | 5.94% | 6.58% | 8.82% | 10.25% | 10.43% | 7.91% | - |
Other Operating Expenses | 0 | 162K | 0 | 0 | 0 | 0 | 0 | 22.8M | -1.14M | -2.14M |
Operating Income | -4.59M▲ 0% | -51.56M▼ 1022.8% | -29.85M▲ 42.1% | 26.7M▲ 189.4% | 72.22M▲ 170.5% | 22.3M▼ 69.1% | 12.53M▼ 43.8% | -1.28M▼ 110.2% | 55.87M▲ 4454.6% | 11.02M▲ 0% |
Operating Margin % | - | -26.65% | -11.44% | 7.89% | 15.45% | 4.95% | 2.89% | -0.27% | 9.92% | 2.14% |
Operating Income Growth % | -2300.23% | -1022.78% | 42.09% | 189.44% | 170.48% | -69.12% | -43.84% | -110.24% | 4454.56% | - |
EBITDA | 1.04M | -44.58M | -20.03M | 34.88M | 88.89M | 40.34M | 35.97M | 15.74M | 82.81M | 44.04M |
EBITDA Margin % | - | -23.04% | -7.67% | 10.31% | 19.02% | 8.95% | 8.31% | 3.27% | 14.71% | 8.58% |
EBITDA Growth % | 596.49% | -4402.21% | 55.07% | 274.17% | 154.83% | -54.63% | -10.81% | -56.24% | 425.99% | 2451.56% |
D&A (Non-Cash Add-back) | 5.63M | 6.98M | 9.83M | 8.18M | 16.68M | 18.03M | 23.45M | 17.03M | 26.94M | 33.02M |
EBIT | -6.54M | -53.96M | -29.56M | 29.04M | 70.32M | 22.29M | 12.58M | -1.26M | 55.87M | 11.02M |
Net Interest Income | -8.01M | -10.79M | -9M | -11.28M | -7.24M | -2.01M | -2.19M | -1.54M | 2.28M | 1.46M |
Interest Income | 0 | 64K | 0 | 0 | 0 | 0 | 0 | 0 | 2.28M | 1.46M |
Interest Expense | 8.01M | 10.85M | 9M | 11.28M | 7.24M | 2.01M | 2.19M | 1.54M | 0 | 0 |
Other Income/Expense | 3.4M | -13.19M | -8.71M | -8.94M | -9.13M | -2.02M | -2.13M | -1.52M | -8.9M | -6.74M |
Pretax Income | -2.09M▲ 0% | -64.75M▼ 2992.2% | -38.56M▲ 40.4% | 17.76M▲ 146.1% | 63.09M▲ 255.1% | 20.28M▼ 67.9% | 10.39M▼ 48.8% | -2.81M▼ 127.0% | 46.97M▲ 1773.3% | 4.28M▲ 0% |
Pretax Margin % | - | -33.47% | -14.77% | 5.25% | 13.5% | 4.5% | 2.4% | -0.58% | 8.34% | 0.83% |
Income Tax | -52.52K | 84K | 150K | 530K | -31.12M | 4.75M | 5.45M | -3.67M | 9.94M | 4.56M |
Effective Tax Rate % | 2.51% | -0.13% | -0.39% | 2.98% | -49.32% | 23.42% | 52.42% | 130.67% | 21.16% | 106.64% |
Net Income | -2.09M▲ 0% | -64.83M▼ 2996.2% | -38.71M▲ 40.3% | 17.23M▲ 144.5% | 94.2M▲ 446.6% | 15.53M▼ 83.5% | 4.95M▼ 68.2% | 861K▼ 82.6% | 37.03M▲ 4201.0% | -284K▲ 0% |
Net Margin % | - | -33.51% | -14.83% | 5.09% | 20.16% | 3.44% | 1.14% | 0.18% | 6.58% | -0.06% |
Net Income Growth % | -903.32% | -2996.16% | 40.29% | 144.52% | 446.61% | -83.51% | -68.16% | -82.59% | 4201.05% | 98.21% |
Net Income (Continuing) | -2.09M | -64.83M | -38.71M | 17.23M | 94.2M | 15.53M | 4.95M | 861K | 37.03M | -284K |
Discontinued Operations | -3.09M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.03▲ 0% | -0.94▼ 2765.9% | -0.44▲ 53.2% | 0.15▲ 134.1% | 0.70▲ 366.7% | 0.12▼ 82.9% | 0.04▼ 68.9% | -0.01▼ 126.8% | 0.15▲ 1600.0% | -0.00▲ 0% |
EPS Growth % | -34.98% | -2765.85% | 53.19% | 134.09% | 366.67% | -82.86% | -68.92% | -126.81% | 1600% | 4.81% |
EPS (Basic) | -0.03 | -0.94 | -0.44 | 0.16 | 0.73 | 0.12 | 0.04 | -0.01 | 0.16 | - |
Diluted Shares Outstanding | 63.88M | 69.32M | 92.84M | 111.36M | 133.66M | 132.38M | 132.75M | 131.67M | 130.25M | 127.8M |
Basic Shares Outstanding | 63.88M | 68.97M | 92.84M | 107.74M | 128.33M | 130.07M | 131.23M | 131.67M | 126.74M | 127.8M |
Dividend Payout Ratio | - | - | - | - | - | - | - | 208.83% | - | - |
ORGO Balance Sheet
Organogenesis Holdings Inc. (ORGO) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 294.44K | 71.13M | 125.6M | 174.34M | 226.98M | 222.61M | 225.04M | 285.94M | 362.19M | 268.5M |
Cash & Short-Term Investments | 125.89K | 21.29M | 60.17M | 84.39M | 113.93M | 102.48M | 104.34M | 135.57M | 93.68M | 92.1M |
Cash Only | 125.89K | 21.29M | 60.17M | 84.39M | 113.93M | 102.48M | 104.34M | 135.57M | 93.68M | 92.1M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 0 | 34.08M | 39.36M | 56.8M | 82.46M | 89.45M | 82M | 109.86M | 217.45M | 116.91M |
Days Sales Outstanding | - | 64.3 | 55.05 | 61.29 | 64.4 | 72.41 | 69.1 | 83.19 | 140.97 | 110.79 |
Inventory | 0 | 13.32M | 22.92M | 27.8M | 25.02M | 24.78M | 28.25M | 26.22M | 29.63M | 28.43M |
Days Inventory Outstanding | - | 70.66 | 110.14 | 116.2 | 79.97 | 86.13 | 96.85 | 82.68 | 78.63 | 78.48 |
Other Current Assets | 0 | 353K | 1.1M | 584K | 711K | 5.1M | 1.19M | 5.67M | 21.43M | 31.07M |
Total Non-Current Assets | 312.5M | 92.55M | 95.09M | 115.87M | 216.28M | 226.75M | 234.98M | 211.94M | 236.54M | 251.49M |
Property, Plant & Equipment | 0 | 39.62M | 47.18M | 55.79M | 128.3M | 145.66M | 156.35M | 126.24M | 159.46M | 157.82M |
Fixed Asset Turnover | - | 4.88x | 5.53x | 6.06x | 3.64x | 3.10x | 2.77x | 3.82x | 3.53x | 3.81x |
Goodwill | 0 | 25.54M | 25.54M | 28.77M | 28.77M | 28.77M | 28.77M | 28.77M | 28.77M | 28.77M |
Intangible Assets | 0 | 26.09M | 20.8M | 30.62M | 25.67M | 20.79M | 15.87M | 12.47M | 9.14M | 3.44M |
Long-Term Investments | 312.5M | 477K | 0 | 0 | 0 | 0 | 15.87M | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 579K | 1.44M | 670K | 1.54M | 1.52M | -9.88M | 5M | 9.2M | 16.13M |
Total Assets | 312.79M▲ 0% | 163.68M▼ 47.7% | 220.69M▲ 34.8% | 290.22M▲ 31.5% | 443.26M▲ 52.7% | 449.36M▲ 1.4% | 460.02M▲ 2.4% | 497.89M▲ 8.2% | 598.73M▲ 20.3% | 519.99M▲ 0% |
Asset Turnover | - | 1.18x | 1.18x | 1.17x | 1.05x | 1.00x | 0.94x | 0.97x | 0.94x | 0.98x |
Asset Growth % | 0.44% | -47.67% | 34.83% | 31.51% | 52.73% | 1.38% | 2.37% | 8.23% | 20.25% | 49.8% |
Total Current Liabilities | 3.93M | 66.39M | 59.89M | 68.22M | 82.7M | 75.02M | 80.51M | 77.48M | 100.12M | 76.02M |
Accounts Payable | 19.05M | 19.16M | 28.39M | 23.38M | 29.34M | 32.33M | 30.72M | 28.91M | 31.95M | 28.61M |
Days Payables Outstanding | 1.51K | 101.66 | 136.43 | 97.73 | 93.77 | 112.36 | 105.32 | 91.17 | 84.8 | 78.38 |
Short-Term Debt | 100K | 2.54M | 0 | 16.67M | 2.66M | 4.54M | 5.49M | 0 | 18.64M | 9.72M |
Deferred Revenue (Current) | 0 | 30.41M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.68M |
Other Current Liabilities | -30.01M | 22.22M | 25.58M | 21.58M | 29.44M | 9.33M | 22.17M | 25.29M | 49.53M | 37.68M |
Current Ratio | 0.07x | 1.07x | 2.10x | 2.56x | 2.74x | 2.97x | 2.80x | 3.69x | 3.62x | 3.53x |
Quick Ratio | 0.07x | 0.87x | 1.71x | 2.15x | 2.44x | 2.64x | 2.44x | 3.35x | 3.32x | 3.16x |
Cash Conversion Cycle | - | 33.3 | 28.76 | 79.76 | 50.6 | 46.18 | 60.63 | 74.7 | 134.81 | 110.89 |
Total Non-Current Liabilities | 10.85M | 50.25M | 105.21M | 80.19M | 119.22M | 108.67M | 100.85M | 35.09M | 64.69M | 62.62M |
Long-Term Debt | 0 | 39.06M | 83.12M | 53.04M | 70.77M | 66.23M | 60.74M | 0 | 50.71M | 0 |
Capital Lease Obligations | 12.39M | 10.15M | 14.43M | 11.44M | 46.89M | 41.31M | 38.9M | 34.2M | 63.49M | 186.7M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | -1.54M | 903K | 7.66M | 15.71M | 1.56M | 1.12M | 1.21M | 894K | -49.51M | 1.49M |
Total Liabilities | 14.78M | 116.64M | 165.1M | 148.41M | 201.92M | 183.69M | 181.36M | 112.57M | 164.81M | 138.65M |
Total Debt | 17.86M | 59.26M | 100.61M | 84.77M | 132.3M | 123.79M | 119.35M | 43.31M | 132.84M | 70.86M |
Net Debt | 17.73M | 37.97M | 40.43M | 377K | 18.37M | 21.31M | 15.01M | -92.26M | 39.16M | -21.24M |
Debt / Equity | 0.06x | 1.26x | 1.81x | 0.60x | 0.55x | 0.47x | 0.43x | 0.11x | 0.31x | 0.19x |
Debt / EBITDA | 17.24x | - | - | 2.43x | 1.49x | 3.07x | 3.32x | 2.75x | 1.60x | 1.61x |
Net Debt / EBITDA | 17.11x | - | - | 0.01x | 0.21x | 0.53x | 0.42x | -5.86x | 0.47x | -0.48x |
Interest Coverage | -0.82x | -4.97x | -3.29x | 2.57x | 9.72x | 11.10x | 5.75x | -0.82x | - | - |
Total Equity | 298.01M▲ 0% | 47.04M▼ 84.2% | 55.58M▲ 18.2% | 141.81M▲ 155.1% | 241.34M▲ 70.2% | 265.67M▲ 10.1% | 278.66M▲ 4.9% | 385.32M▲ 38.3% | 433.92M▲ 12.6% | 381.35M▲ 0% |
Equity Growth % | -0.7% | -84.22% | 18.16% | 155.13% | 70.18% | 10.08% | 4.89% | 38.27% | 12.61% | 91.87% |
Book Value per Share | 4.67 | 0.68 | 0.60 | 1.27 | 1.81 | 2.01 | 2.10 | 2.93 | 3.33 | 2.98 |
Total Shareholders' Equity | 298.01M | 47.04M | 55.58M | 141.81M | 241.34M | 265.67M | 278.66M | 385.32M | 433.92M | 381.35M |
Common Stock | 293.01M | 9K | 10K | 13K | 13K | 13K | 13K | 13K | 13K | 13K |
Retained Earnings | -2.33M | -130.24M | -171.01M | -155.03M | -60.83M | -45.3M | -40.97M | -40.11M | -3.08M | -56.23M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -293.01M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ORGO Cash Flow Statement
Organogenesis Holdings Inc. (ORGO) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -586.6K | -60.74M | -33.53M | 5.47M | 61.98M | 24.86M | 30.92M | 14.21M | -10.31M | 30.75M |
Operating CF Margin % | - | -31.4% | -12.85% | 1.62% | 13.26% | 5.51% | 7.14% | 2.95% | -1.83% | - |
Operating CF Growth % | -4.33% | -10254.34% | 44.8% | 116.3% | 1033.88% | -59.89% | 24.37% | -54.04% | -172.56% | -392% |
Net Income | -2.09M | -64.83M | -40.45M | 17.23M | 94.9M | 15.53M | 4.95M | 861K | 37.03M | -284K |
Depreciation & Amortization | 5.63M | 6.98M | 9.43M | 8.18M | 16.68M | 10.73M | 23.45M | 17.03M | 26.94M | 30.95M |
Stock-Based Compensation | 919K | 1.07M | 936K | 1.66M | 3.86M | 6.55M | 9M | 10.58M | 13.3M | 6.87M |
Deferred Taxes | 0 | 186K | 111K | 112K | -31.98M | 1.98M | 2.01M | -10.72M | 9.5M | -4.61M |
Other Non-Cash Items | -155.75K | 18.25M | 6.12M | 6.03M | 17.8M | 24.15M | 9.59M | 45.35M | 35.3M | 35.97M |
Working Capital Changes | 1.51M | -22.4M | -9.67M | -27.76M | -39.29M | -34.08M | -18.07M | -48.89M | -132.38M | -41.14M |
Change in Receivables | -7.01M | -7.11M | -4.69M | -17.57M | -30.23M | -8.77M | 5.54M | -31.8M | -115.8M | -16.97M |
Change in Inventory | -1.49M | -5M | -11.06M | -6.7M | -9.3M | -9.41M | 6.58M | -6.2M | -17.91M | -17.91M |
Change in Payables | 0 | -60K | 4.7M | -4.1M | 3.85M | 3.26M | -108K | -2.37M | -528K | -35K |
Cash from Investing | -14.87M | -1.86M | -6.23M | -23.5M | -31.22M | -33.9M | -24.36M | -10.03M | -14.15M | -13.67M |
Capital Expenditures | -2.43M | -1.86M | -6.23M | -17.68M | -31.22M | -33.9M | -24.36M | -10.03M | -14.15M | -13.67M |
CapEx % of Revenue | - | 0.96% | 2.39% | 5.23% | 6.68% | 7.52% | 5.63% | 2.08% | 2.51% | 2.66% |
Acquisitions | -11.79M | 1K | 0 | -5.82M | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -658K | 1K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash from Financing | -327.58K | 81.64M | 78.73M | 42.47M | -1.04M | -2.2M | -5.5M | 27.64M | -17.36M | -35.52M |
Debt Issued (Net) | 100K | 1.07M | 37.23M | -15.91M | -2.01M | -3.01M | -5.17M | -67.64M | -1.17M | -10.73M |
Equity Issued (Net) | -427.58K | -151K | -8.84M | 64.73M | 2.2M | 0 | 0 | 95.21M | 157K | 132K |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1.8M | 0 | 0 |
Share Repurchases | 0 | 0 | -6.76M | 0 | 0 | 0 | 0 | -25.48M | 0 | 0 |
Other Financing | 19.19M | 80.72M | 50.34M | -6.35M | -1.22M | 814K | -332K | 1.87M | -16.35M | -24.92M |
Net Change in Cash | -914.18K▲ 0% | 19.05M▲ 2183.5% | 38.97M▲ 104.6% | 24.44M▼ 37.3% | 29.72M▲ 21.6% | -11.24M▼ 137.8% | 1.05M▲ 109.3% | 31.81M▲ 2935.6% | -41.82M▼ 231.5% | -18.43M▲ 0% |
Free Cash Flow | -3.01M▲ 0% | -62.6M▼ 1977.8% | -39.76M▲ 36.5% | -12.21M▲ 69.3% | 30.76M▲ 351.9% | -9.04M▼ 129.4% | 6.55M▲ 172.5% | 4.18M▼ 36.3% | -24.46M▼ 685.7% | 17.08M▲ 0% |
FCF Margin % | - | -32.36% | -15.24% | -3.61% | 6.58% | -2% | 1.51% | 0.87% | -4.34% | 3.33% |
FCF Growth % | -56.64% | -1977.8% | 36.48% | 69.29% | 351.87% | -129.39% | 172.5% | -36.27% | -685.73% | 343.99% |
FCF per Share | -0.05 | -0.90 | -0.43 | -0.11 | 0.23 | -0.07 | 0.05 | 0.03 | -0.19 | 0.13 |
FCF Conversion (FCF/Net Income) | 0.28x | 0.94x | 0.87x | 0.32x | 0.66x | 1.60x | 6.25x | 16.50x | -0.28x | -60.15x |
Interest Paid | 6.08M | 5.42M | 8.15M | 9.61M | 5.79M | 2.65M | 5.44M | 4.97M | 0 | 0 |
Taxes Paid | 96K | 8K | 49K | 61K | 607K | 1.2M | 3.05M | 6.96M | 0 | 3.64M |
ORGO Key Ratios
Organogenesis Holdings Inc. (ORGO) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -0.7% | -37.58% | -75.44% | 17.46% | 49.17% | 6.13% | 1.82% | 0.26% | 9.04% | -0.07% |
Return on Invested Capital (ROIC) | -1.12% | -19.3% | -24.74% | 16.81% | 26.95% | 6.12% | 3.24% | -0.33% | 10.94% | 2.17% |
Gross Margin | - | 64.43% | 70.9% | 74.19% | 75.56% | 76.71% | 75.42% | 75.99% | 75.57% | 70.41% |
Net Margin | - | -33.51% | -14.83% | 5.09% | 20.16% | 3.44% | 1.14% | 0.18% | 6.58% | -0.06% |
Debt / Equity | 0.06x | 1.26x | 1.81x | 0.60x | 0.55x | 0.47x | 0.43x | 0.11x | 0.31x | 0.19x |
Interest Coverage | -0.82x | -4.97x | -3.29x | 2.57x | 9.72x | 11.10x | 5.75x | -0.82x | - | - |
FCF Conversion | 0.28x | 0.94x | 0.87x | 0.32x | 0.66x | 1.60x | 6.25x | 16.50x | -0.28x | -60.15x |
Revenue Growth | - | - | 34.91% | 29.63% | 38.15% | -3.52% | -3.94% | 11.29% | 16.8% | 11.95% |
Related:ORGO Dividend History·ORGO Revenue History·ORGO Price History·ORGO P/E History·ORGO Financial Ratios·ORGO Institutional Holders
ORGO SEC Filings & Documents
Organogenesis Holdings Inc. (ORGO) SEC filings — annual & quarterly reports (10-K, 10-Q)
ORGO Frequently Asked Questions
Organogenesis Holdings Inc. (ORGO) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Organogenesis Holdings Inc. (ORGO) reported $513.6M in revenue for fiscal year 2025.
Organogenesis Holdings Inc. (ORGO) grew revenue by 16.8% over the past year. This is strong growth.
Organogenesis Holdings Inc. (ORGO) reported a net loss of $0.3M for fiscal year 2025.
Dividend & Returns
Organogenesis Holdings Inc. (ORGO) has a return on equity (ROE) of 9.0%. This is below average, suggesting room for improvement.
Organogenesis Holdings Inc. (ORGO) generated $17.1M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.